-
Je něco špatně v tomto záznamu ?
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
M. Babjuk, M. Burger, EM. Compérat, P. Gontero, AH. Mostafid, J. Palou, BWG. van Rhijn, M. Rouprêt, SF. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, JLD. Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- invazivní růst nádoru MeSH
- lidé MeSH
- management péče o pacienta * metody normy MeSH
- nádory močového měchýře * patologie terapie MeSH
- směrnice pro lékařskou praxi jako téma normy MeSH
- společnosti lékařské MeSH
- staging nádorů MeSH
- urologie * metody trendy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). OBJECTIVE: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of <5, one immediate chemotherapy instillation is recommended. Patients with intermediate-risk tumours should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-unresponsive tumours. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC. The recommendations are based on the current literature (until the end of 2018), with emphasis on high-level data from randomised clinical trials and meta-analyses. Stratification of patients into low-, intermediate-, and high-risk groups is essential for deciding appropriate use of adjuvant intravesical chemotherapy or bacillus Calmette-Guérin (BCG) instillations. Surgical removal of the bladder should be considered in case of BCG-unresponsive tumours or in NMIBCs with the highest risk of progression.
Department of Urology Caritas St Josef Medical Centre University of Regensburg Regensburg Germany
Department of Urology Fundació Puigvert Universitat Autònoma de Barcelona Barcelona Spain
Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Urology Hospital Universitario Fundación Alcorcón Madrid Spain
Department of Urology Medical University of Graz Graz Austria
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology Royal Free London NHS Foundation Trust London UK
Department of Urology Royal Surrey County Hospital Guildford Surrey UK
Department of Urology University of Rennes Rennes France
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Molinette Hospital University of Studies of Torino Torino Italy
European Association of Urology Guidelines Office Brussels Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028766
- 003
- CZ-PrNML
- 005
- 20210114155130.0
- 007
- ta
- 008
- 210105s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2019.08.016 $2 doi
- 035 __
- $a (PubMed)31443960
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Babjuk, Marko $u Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: Marek.Babjuk@fnmotol.cz.
- 245 10
- $a European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update / $c M. Babjuk, M. Burger, EM. Compérat, P. Gontero, AH. Mostafid, J. Palou, BWG. van Rhijn, M. Rouprêt, SF. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, JLD. Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup,
- 520 9_
- $a CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). OBJECTIVE: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of <5, one immediate chemotherapy instillation is recommended. Patients with intermediate-risk tumours should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-unresponsive tumours. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC. The recommendations are based on the current literature (until the end of 2018), with emphasis on high-level data from randomised clinical trials and meta-analyses. Stratification of patients into low-, intermediate-, and high-risk groups is essential for deciding appropriate use of adjuvant intravesical chemotherapy or bacillus Calmette-Guérin (BCG) instillations. Surgical removal of the bladder should be considered in case of BCG-unresponsive tumours or in NMIBCs with the highest risk of progression.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a staging nádorů $7 D009367
- 650 12
- $a management péče o pacienta $x metody $x normy $7 D010346
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 12
- $a nádory močového měchýře $x patologie $x terapie $7 D001749
- 650 12
- $a urologie $x metody $x trendy $7 D014572
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Burger, Maximilian $u Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
- 700 1_
- $a Compérat, Eva M $u Department of Pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, UPMC Paris VI, Paris, France.
- 700 1_
- $a Gontero, Paolo $u Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy.
- 700 1_
- $a Mostafid, A Hugh $u Department of Urology, Royal Surrey County Hospital, Guildford, Surrey, UK.
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 700 1_
- $a van Rhijn, Bas W G $u Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 700 1_
- $a Rouprêt, Morgan $u Urology Department, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 700 1_
- $a Sylvester, Richard $u European Association of Urology Guidelines Office, Brussels, Belgium.
- 700 1_
- $a Zigeuner, Richard $u Department of Urology, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Capoun, Otakar $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Cohen, Daniel $u Department of Urology, Royal Free London NHS Foundation Trust, London, UK.
- 700 1_
- $a Escrig, José Luis Dominguez $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
- 700 1_
- $a Hernández, Virginia $u Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
- 700 1_
- $a Peyronnet, Benoit $u Department of Urology, University of Rennes, Rennes, France.
- 700 1_
- $a Seisen, Thomas $u Urology Department, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 76, č. 5 (2019), s. 639-657
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31443960 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114155129 $b ABA008
- 999 __
- $a ok $b bmc $g 1609101 $s 1119946
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 76 $c 5 $d 639-657 $e 20190820 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20210105
